Results 31 to 40 of about 118,861 (266)

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

BMC Cancer, 2021
Background The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increase ...
Alison K. Yoder, David S. Lakomy, Yongquan Dong, Suchismita Raychaudhury, Kathryn Royse, Christine Hartman, Peter Richardson, Donna L. White, Jennifer R. Kramer, Lilie L. Lin, Elizabeth Chiao   +10 more
doaj   +1 more source

Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance

, 2020
The HIV-1 protease is a major target of inhibitor drugs in AIDS therapies. The therapies are impaired by mutations of the HIV-1 protease that can lead to resistance to protease inhibitors.
Hemmateenejad, B., Weikl, T.
core   +1 more source

Personalizing HIV therapy, mission impossible? [PDF]

, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease

Biology, 2012
Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and ...
Ladislau C. Kovari, Iulia A. Kovari, Joseph S. Brunzelle, Samuel J. Reiter, Zhigang Liu, Tamaria G. Dewdney, Yong Wang   +6 more
doaj   +1 more source

Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay. [PDF]

, 2011
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide.
Agudelo, Juliet, Amberg, Sean M, Chen, Yen Ting, Craik, Charles S, Goetz, David H, Hansell, Elizabeth, Lu, Kai, McKerrow, James, Roush, William R, Simmons, Graham, Zhou, Yanchen   +10 more
core   +1 more source

HIV-1 Protease Inhibitors [PDF]

Clinical Infectious Diseases, 2000
Treatment of human immunodeficiency virus type 1 (HIV-1) infection with regimens that include protease inhibitors (PIs) has contributed to marked improvements in HIV-related disease progression and mortality. Five PIs are approved by the US Food and Drug Administration and have potent activity in vitro.
openaire   +2 more sources

Molecular Basis for Drug Resistance in HIV-1 Protease

Viruses, 2010
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer, Kelly Thayer, Ellen A. Nalivaika, Ayşegül Özen, Moses M. Prabu-Jeyabalan, Madhavi N.L. Nalam, Nancy M. King, Rajintha M. Bandaranayake, Jennifer F. Murzycki, Seema Mittal, Madhavi Kolli, Yufeng Cai, Akbar Ali   +12 more
doaj   +1 more source

Novel wild type and mutate HIV-1 protease inhibitors containing heteroaryl carboxamides in P2: Synthesis, biological evaluations and in silico ADME prediction

Results in Chemistry, 2023
The Virus HIV-1 infection still represents a serious disease even if actually it is transformed in chronic pathology. Considering the crucial role of the enzyme Protease in life cycle of HIV many efforts have been made in the research of new organic ...
Maria Francesca Armentano, Paolo Lupattelli, Faustino Bisaccia, Rosarita D'Orsi, Rocchina Miglionico, Ilaria Nigro, Alessandro Santarsiere, Federico Berti, Maria Funicello, Lucia Chiummiento   +9 more
doaj   +1 more source

Sechs historische Grabsteine, um 1700, vom Alten Friedhof in Gießen [PDF]

, 1994
In this work, we applied a coarse-grained molecular dynamics method for simulating inhibitors entering the binding cavity of human immunodeficiency virus type 1 protease (HIV-1 PR).
Huang, Yonggang, Hwang, K. C., Ji, Baohua, Li, Dechang, Liu, Ming S.   +4 more
core   +1 more source

HIV protease inhibitors and atherosclerosis [PDF]

Journal of Clinical Investigation, 2003
The advent of highly active antiretroviral therapy (HAART), including the use of HIV protease inhibitors (PIs) has significantly reduced the morbidity and mortality of AIDS in HIV infected patients. Unfortunately, the adverse effects of PIs, including dyslipidemia, lipodystrophy, insulin resistance, and premature atherosclerosis, are cause for concern ...
openaire   +2 more sources